Navigation Links
Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
Date:1/15/2008

SAN MATEO, Calif., Jan. 15 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported preliminary results of a second Phase IIb clinical trial of A-002, for the treatment of cardiovascular disease. In this second study, administration of once-daily A-002 lowered both sPLA2 and LDL-C levels confirming the positive effects of A-002 treatment seen in the twice-daily PLASMA study (Phospholipase Levels And Serological Markers of Atherosclerosis) announced in October 2007.

The second trial was a multi-center, randomized, double-blind, placebo- controlled trial that enrolled approximately 140 patients with stable coronary heart disease in the U.S. Subjects were randomized to receive one of two different daily doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was reduction in secretory phospholipase A2 (sPLA2) levels. Secondary endpoints included a number of lipid and inflammatory biomarkers. The Company plans to present data from the Phase IIb trial at scientific meetings in 2008.

"We are extremely pleased to validate the findings of our first PLASMA study, with once-a-day dosing of A-002 which further enhances our development and commercial flexibility," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "We look forward to meeting with the FDA to discuss our plans for Phase III. We expect the registration program will target patients with coronary heart disease with associated hyperlipidemia and inflammation who are currently not achieving adequate cholesterol control with diet, exercise, and existing statin therapies such as Lipitor(R)."

Data from the first PLASMA trial demonstrated that in addition to lowering sPLA2, treatment with A-002 resulted in significant reductions in blood levels of total cholesterol, Non-High Density Lipoprotein Cholesterol (non HDL-C), and Low Dens
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...   About ELISA test ELISA test ... is used for measuring the concentration of analytes such ... various types of enzymes such as carbonic anhydrase, glucose ... by photometry or fluorometry. ELISA is used as a ... such as HIV, pernicious anemia, rotavirus, Rocky Mountain spotted ...
(Date:9/2/2015)... 2015 STAAR Surgical Company (NASDAQ: STAA ), ... delivery systems for the eye, today announced that its Board ... the Company,s Board. Mr. Wall was formerly ... -based investment firm, for more than nine years. Mr. ... and chair of the Corporate Governance Committee and member of ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... the "Inhaled Drug Delivery (London, UK - November ... This Inhaled Drug Delivery meeting will cover industry case ... much more. The Co-Chairmen are Dr Steven Nichols ... Senior Director, Mylan. Companies participating include: ...
Breaking Medicine Technology:Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2
... NEW YORK, Dec. 13, 2010 Pfizer Inc. (NYSE: ... Directors has elected George A. Lorch, 68, who has served ... the Board, effective immediately. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ... said, "George Lorch has been a valuable, independent voice on ...
... Company announced today that it has suspended its global ... compound, as a second-line treatment for those with unresectable ... with an independent data monitoring committee, recommended a "full ... hold ensures that no new or existing patients in ...
Cached Medicine Technology:Pfizer Board of Directors Elects George A. Lorch Non-Executive Chairman 2Lilly Suspends Phase III Trial in Metastatic Melanoma 2Lilly Suspends Phase III Trial in Metastatic Melanoma 3
(Date:9/3/2015)... York, New York (PRWEB) , ... September 03, 2015 , ... ... of the Division of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell Medical ... College. , Dr. Winchell is a nationally renowned expert in care for the critically ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Global Vision ... that it will be spotlighting its award-winning print and artwork inspection solutions, ScanProof ... September 16 and 17 at the Olympia London, booth #F33 , Be the first ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... its upcoming virtual conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” ... Health, Express Scripts and Milliman, will discuss how plan sponsors are adopting bold, ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Hunters Creek ... Survivor Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited ... for friends and family to enjoy Thanksgiving and Christmas with an extra big smile. ...
(Date:9/3/2015)... ... ... ProScrub is a set of automated tools that allow Final Cut Pro ... without the use of keyframes. Utilize ProScrub's powerful sliders to determine the number ... to energetic video productions. ProScrub is a Final Cut Pro X ...
Breaking Medicine News(10 mins):Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... foods have a reputation for being full of flavor. ... for generations are,being prepared now in ways that can ... with high-calorie ingredients that,are fried or full of salt ... foods high in fat and calories can place people,at ...
... In New National Guidelines, WASHINGTON, Sept. 5 ... are getting a back-to-school boost,from the new asthma care ... primary importance of patient education,programs -- not just treatment ... their quality of life., Millions of children with ...
... Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty ... U.S. Food and Drug,Administration (FDA) product approval at its ... plans to seek FDA approval to,manufacture additional solid dosage ... is expected to be producing over 1 billion tablets,and ...
... Alliance is,offering an innovative program to help military leaders ... service to our country. Responding to the,needs of National ... author and nationally certified counselor, Joanne Steen, a widow,of ... Through a first-of-its-kind partnership, TriWest and Steen will ...
... Stahl Cowen Crowley LLC, of Chicago,IL, counsel to the ... Dana Corporation, Inc. has entered into a settlement,agreement with ... Dana had sought Bankruptcy Court approval to terminate all ... of the settlement Stahl,Cowen Crowley negotiated on behalf of ...
... Pet Owners to ... Surprise Attack, SACRAMENTO, Calif., Sept. 4 Most Californians ... encounters between,homeowners and wandering wildlife have prompted the California Veterinary,Medical ... what to,do to prevent an attack and how to react ...
Cached Medicine News:Health News:Top Tips to Enjoy Healthy Latin Food Without Losing the Taste (Recipe) 2Health News:Top Tips to Enjoy Healthy Latin Food Without Losing the Taste (Recipe) 3Health News:School is Cool for Asthma Patients of All Ages 2Health News:Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility 2Health News:TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program 2Health News:Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee 2Health News:Wildlife Sightings on the Rise in California 2Health News:Wildlife Sightings on the Rise in California 3
Urea nitrogen (BUN) liquid reagent is used for the kinetic quantitative determination of Urea Nitrogen (BUN) in human serum used in routine examination and monitoring of therapy and relapses....
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C....
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... microplate spectrophotometer designed specifically to run 24 ... With rugged hardware, proven optical performance and ... of traditional spectrophotometry to obtain results quickly, ... read up to eight, 1 cm Biocell ...
Medicine Products: